Congo to Receive 70,000 Ebola Vaccine Doses Amid Outbreak
The Democratic Republic of Congo is set to receive 70,000 doses of the Ervebo Ebola vaccine, a move by the World Health Organization and partners to bolster efforts against the current rapid Ebola outbreak. While Ervebo is licensed for a…
Detroit, MI, August 20, 2026 —
The Democratic Republic of Congo is preparing to receive 70,000 doses of the Ervebo Ebola vaccine as part of an initiative by the World Health Organization (WHO) and its partners to counter the ongoing rapid Ebola outbreak in the region.
The vaccine doses are intended for a clinical trial and to provide vaccination for frontline health workers engaged in combating the outbreak. This effort aims to bolster existing public health responses.
Ervebo is currently licensed for use against a different strain of the Ebola virus. However, preliminary data indicates that it may offer a degree of protection against the Bundibugyo virus, which is identified as the cause of the current outbreak in eastern Congo. Further research through the planned clinical trial is expected to provide more information on its efficacy in this context.
The deployment of these vaccines is a significant step in the international community’s support for the Democratic Republic of Congo’s public health infrastructure as it confronts the challenging outbreak.
Story summarized from the original created by Associated Press on www.clickondetroit.com, see more information here.
